Clinical Trial Search

Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05

Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale

Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed

Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants

Primary: Hamilton Depression Rating Scale (HAMD) Scores — 16.76; 17.65; 1.67; 16.24 score on a scale

Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells

Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses

Primary: Methamphetamine Use During Intervention — 65.17; 60.35; 57.74; 42.81 percentage of negative urine samples — p=<0.01

Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05

Primary: HAMD Rating Scores — 16.86; 10.71; 9.81; 7.33 Units on a scale

Primary: Methamphetamine Abstinence

Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg

Primary: End of Treatment Abstinence — 5; 4 Participants

Primary: Heart Rate — 79.66 beats per minute

Primary: Functional Connectivity During Resting State Magnetic Resonance Imaging (MRI) — 0.91; 0.52; 0.54; 0.32 Fisher's Z-score

Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens

Primary: Self-report Effects of High. — 0; 0; 0; 0 units on a scale

Primary: Methamphetamine Days of Abstinence : Proportion of Days Abstinent — .56; .55; .74; .74 proportion of days abstinent — p=.47

Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices

Primary: Effect of Entacapone on Methamphetamine-induced Mood — 12.500; 13.750; 7.500; 9.833 units on a scale

Primary: Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo — 0.3025; 0.3850 total amount consumed in grams

Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05

Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants

Primary: Change in MA Positive Urine Drug Screens Among Participants Randomly Assigned to Receive Varenicline Versus Placebo. — 7.4; 2.3 total MA-free urine drug screens

Primary: Retention in the Study — 28.2; 45.4 Days — p=0.1760

Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased

Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days

Primary: Increase in HIV Viral Suppression for HIV-positive Participants: High- vs. Low-Intensity Frontline Intervention With SMS in Stage 2 — 31; 35; 6; 3 Participants — p=0.447

Primary: Number of Subjects Showing Abstinence — 14; 20 Participants